TY - JOUR
T1 - Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells
AU - Ziegler, C. G.
AU - Ullrich, M.
AU - Schally, A. V.
AU - Bergmann, R.
AU - Pietzsch, J.
AU - Gebauer, L.
AU - Gondek, K.
AU - Qin, N.
AU - Pacak, K.
AU - Ehrhart-Bornstein, M.
AU - Eisenhofer, G.
AU - Bornstein, S. R.
N1 - Funding Information:
This work was supported by The Deutsche Forschungsgemeinschaft (Grants ZI-1362/2-1 (C.G.Z. & G.E.) , and BE-2607/1-1 (R.B. & J.P)) . We are very thankful to Prof. Arthur Tischler and Dr. James Powers for providing us both the MPC as well as the MTT cell lines.
PY - 2013/5/22
Y1 - 2013/5/22
N2 - Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed that these cells are characterized by pronounced expression of the somatostatin receptor 2 (sst2), growth hormone-releasing hormone (GHRH) receptor and the luteinizing hormone-releasing hormone (LHRH) receptor. We further demonstrated significant anti-tumor effects mediated by cytotoxic somatostatin analogs, AN-162 and AN-238, by LHRH antagonist, Cetrorelix, by the cytotoxic LHRH analog, AN-152, and by recently developed GHRH antagonist, MIA-602, on MPC and for AN-152 and MIA-602 on MTT cells. Studies of novel anti-tumor compounds on these mouse cell lines serve as an important basis for mouse models of metastatic pheochromocytoma, which we are currently establishing.
AB - Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed that these cells are characterized by pronounced expression of the somatostatin receptor 2 (sst2), growth hormone-releasing hormone (GHRH) receptor and the luteinizing hormone-releasing hormone (LHRH) receptor. We further demonstrated significant anti-tumor effects mediated by cytotoxic somatostatin analogs, AN-162 and AN-238, by LHRH antagonist, Cetrorelix, by the cytotoxic LHRH analog, AN-152, and by recently developed GHRH antagonist, MIA-602, on MPC and for AN-152 and MIA-602 on MTT cells. Studies of novel anti-tumor compounds on these mouse cell lines serve as an important basis for mouse models of metastatic pheochromocytoma, which we are currently establishing.
KW - Peptide analogs
KW - Pheochromocytoma
KW - Targeted tumor therapy
UR - http://www.scopus.com/inward/record.url?scp=84876093244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876093244&partnerID=8YFLogxK
U2 - 10.1016/j.mce.2012.12.011
DO - 10.1016/j.mce.2012.12.011
M3 - Article
C2 - 23267837
AN - SCOPUS:84876093244
VL - 371
SP - 189
EP - 194
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
SN - 0303-7207
IS - 1-2
ER -